SZSE:300832 (China)
Â
Class A
Â¥
70.15
(+2.56%)
Apr 26
Business Description
Shenzhen New Industries Biomedical Engineering Co Ltd
ISIN : CNE100003T39
Share Class Description:
SZSE:300832: Class ACompare
Compare
Traded in other countries / regions
300832.China IPO Date
2020-05-12Description
Shenzhen New Industries Biomedical Engineering Co Ltd is a bio-medical company specialized in clinical laboratory instruments and in vitro diagnostic reagents. The company produces and sells series of automatic chemiluminescence immunoassay instruments and supporting reagents. Its products include Immunoassay, Clinical Chemistry, Integrated System, Lab Automation, and Reagents.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 603.95 | |||||
| Equity-to-Asset | 0.92 | |||||
| Interest Coverage | 4108.45 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 51.38 | |||||
| Beneish M-Score | -1.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 19.6 | |||||
| 3-Year EBITDA Growth Rate | 19.2 | |||||
| 3-Year EPS without NRI Growth Rate | 19.9 | |||||
| 3-Year FCF Growth Rate | 13.2 | |||||
| 3-Year Book Growth Rate | 16.1 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 74.71 | |||||
| 9-Day RSI | 60.13 | |||||
| 14-Day RSI | 52.18 | |||||
| 6-1 Month Momentum % | 26.53 | |||||
| 12-1 Month Momentum % | 38.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.56 | |||||
| Quick Ratio | 7.01 | |||||
| Cash Ratio | 5.29 | |||||
| Days Inventory | 303 | |||||
| Days Sales Outstanding | 54.72 | |||||
| Days Payable | 50.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1 | |||||
| Dividend Payout Ratio | 0.33 | |||||
| 3-Year Dividend Growth Rate | -3.9 | |||||
| Forward Dividend Yield % | 1 | |||||
| 5-Year Yield-on-Cost % | 1.02 | |||||
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | 0.99 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 72.96 | |||||
| Operating Margin % | 45.38 | |||||
| Net Margin % | 42.08 | |||||
| FCF Margin % | 27.89 | |||||
| ROE % | 24 | |||||
| ROA % | 22.07 | |||||
| ROIC % | 40.9 | |||||
| ROC (Joel Greenblatt) % | 71.53 | |||||
| ROCE % | 27.27 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 33.24 | |||||
| PE Ratio without NRI | 33.38 | |||||
| Shiller PE Ratio | 64.08 | |||||
| Price-to-Owner-Earnings | 40.07 | |||||
| PEG Ratio | 2.07 | |||||
| PS Ratio | 13.99 | |||||
| PB Ratio | 7.29 | |||||
| Price-to-Tangible-Book | 7.47 | |||||
| Price-to-Free-Cash-Flow | 50.16 | |||||
| Price-to-Operating-Cash-Flow | 38.79 | |||||
| EV-to-EBIT | 26.73 | |||||
| EV-to-EBITDA | 26.73 | |||||
| EV-to-Revenue | 12.88 | |||||
| EV-to-FCF | 46.18 | |||||
| Price-to-Projected-FCF | 4.98 | |||||
| Price-to-DCF (Earnings Based) | 1.46 | |||||
| Price-to-DCF (FCF Based) | 2.92 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.21 | |||||
| Price-to-Graham-Number | 3.33 | |||||
| Price-to-Net-Current-Asset-Value | 12.57 | |||||
| Price-to-Net-Cash | 22.48 | |||||
| Earnings Yield (Greenblatt) % | 3.74 | |||||
| FCF Yield % | 1.99 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shenzhen New Industries Biomedical Engineering Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 3,929.656 | ||
| EPS (TTM) (Â¥) | 2.105 | ||
| Beta | -0.11 | ||
| Volatility % | 38.94 | ||
| 14-Day RSI | 52.18 | ||
| 14-Day ATR (Â¥) | 2.793412 | ||
| 20-Day SMA (Â¥) | 66.6355 | ||
| 12-1 Month Momentum % | 38.33 | ||
| 52-Week Range (Â¥) | 49.86 - 83.5 | ||
| Shares Outstanding (Mil) | 785.72 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shenzhen New Industries Biomedical Engineering Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shenzhen New Industries Biomedical Engineering Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shenzhen New Industries Biomedical Engineering Co Ltd Frequently Asked Questions
What is Shenzhen New Industries Biomedical Engineering Co Ltd(SZSE:300832)'s stock price today?
The current price of SZSE:300832 is ¥70.15. The 52 week high of SZSE:300832 is ¥83.50 and 52 week low is ¥49.86.
When is next earnings date of Shenzhen New Industries Biomedical Engineering Co Ltd(SZSE:300832)?
The next earnings date of Shenzhen New Industries Biomedical Engineering Co Ltd(SZSE:300832) is .
Does Shenzhen New Industries Biomedical Engineering Co Ltd(SZSE:300832) pay dividends? If so, how much?
The Dividend Yield %  of Shenzhen New Industries Biomedical Engineering Co Ltd(SZSE:300832) is 1% (As of Today), Highest Dividend Payout Ratio of Shenzhen New Industries Biomedical Engineering Co Ltd(SZSE:300832) was 0.69. The lowest was 0.33. And the median was 0.42. The  Forward Dividend Yield % of Shenzhen New Industries Biomedical Engineering Co Ltd(SZSE:300832) is 1%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers